UBC Acquires Evidinno, Escalating the RWE and Health Economics Race

KING OF PRUSSIA, Pa. – January 06, 2026 – United BioSource LLC (UBC) has acquired Evidinno Outcomes Research Inc., a move that signals a significant escalation in the biopharmaceutical services industry's race to dominate the rapidly growing field of real-world evidence (RWE) and health economics and outcomes research (HEOR).

The acquisition, announced today, brings Vancouver-based Evidinno, a specialized consulting firm known for its scientific rigor and technology-enabled analytics, under the umbrella of UBC, a major player in late-stage and post-approval research. While financial terms were not disclosed, the strategic value is clear: combining UBC’s global scale and data infrastructure with Evidinno’s deep expertise in creating regulatory-grade evidence and economic models.

This consolidation creates a more formidable competitor in a market striving to prove the real-world value of new therapies, a critical hurdle for drug developers seeking regulatory approval and, crucially, reimbursement from payers.

A Strategic Move in a Booming Market

The timing of the acquisition is no coincidence. The RWE and HEOR services markets are experiencing explosive growth, driven by a fundamental shift in healthcare toward value-based models. Industry analysts project the combined market to surge, with some forecasts predicting the RWE solutions market alone could exceed $48 billion by 2032, expanding at a compound annual growth rate (CAGR) of over 13%. Similarly, the HEOR services market is on a trajectory to more than double in the coming years, fueled by increased R&D spending and a rising number of drug approvals.

Regulators like the FDA and payers worldwide are no longer satisfied with clinical trial data alone. They are increasingly demanding robust evidence that demonstrates how a drug performs in diverse, real-world patient populations. This has created an insatiable appetite for the sophisticated data analysis, evidence synthesis, and economic modeling that firms like UBC and Evidinno provide.

By acquiring Evidinno, UBC is not just buying a company; it is acquiring a set of highly sought-after capabilities that directly address the industry's biggest challenges, including data quality limitations and methodological complexities. The move positions UBC to capture a larger share of this lucrative market, equipping it to better serve biopharma clients who need to build a compelling value story for their products from development through the entire product lifecycle.

Fusing Expertise and Technology

The true power of this acquisition lies in the synergy between the two organizations. UBC has built a reputation over two decades for its operational strength in conducting large-scale observational studies and managing complex drug safety programs. Its proprietary “Evidence Engine” provides a powerful, source-agnostic foundation for integrating disparate datasets.

Evidinno, in contrast, brings a boutique level of scientific and methodological depth. The firm is a leader in evidence synthesis, including network meta-analyses and comparative effectiveness research, which are essential for demonstrating how a new drug stacks up against existing treatments. Critically, Evidinno has been a pioneer in integrating artificial intelligence into its workflows. Its use of AI-assisted literature reviews, reportedly leveraging advanced models like GPT-4o mini, dramatically accelerates the evidence-gathering process, reduces human error, and allows its team of seasoned epidemiologists and health economists to focus on high-level strategic analysis.

“Evidinno’s scientific rigor and technology-enabled workflows deepen our ability to curate fit-for-purpose evidence and health economic and outcomes insights for our clients,” said Aaron Berger, SVP of Evidence Development Solutions at UBC, in a statement. “Together, we will transform the evidence value chain and help sponsors answer important questions on the safety and effectiveness of treatments for patients.”

This fusion of UBC's operational muscle with Evidinno's tech-forward, scientifically rigorous approach creates an end-to-end solution that few competitors can match, promising to make the generation of complex evidence faster, smarter, and more reliable.

Navigating the Path to Market Access

For biopharmaceutical companies, getting a drug approved is only half the battle. The other, often more difficult, half is securing market access—convincing payers and health technology assessment (HTA) bodies that the new therapy is worth its price tag. This requires a meticulously constructed evidence package, including HTA dossiers and economic models that justify the product's value.

This is where the combined strength of UBC and Evidinno becomes most impactful. Evidinno’s expertise in developing regulatory- and HTA-grade evidence directly addresses this critical client need. The ability to generate robust data on cost-effectiveness and long-term patient outcomes is paramount in today's budget-constrained healthcare systems.

Dr. Mir Sohail Fazeli, CEO of Evidinno, emphasized this strategic alignment. “By combining our HTA- and regulatory-grade evidence synthesis solutions, real-world research, and economic modeling capabilities with UBC’s global platform, we are well positioned to deliver robust, decision-ready evidence that supports sponsors and improves outcomes for patients world-wide,” he stated.

The integrated offering will help clients navigate the labyrinthine requirements of different global markets, providing the tailored evidence needed to unlock patient access and ensure innovative therapies reach those who need them most.

Reshaping the Competitive Landscape

The UBC-Evidinno deal is the latest in a wave of consolidation sweeping the biopharma services sector. Industry giants like IQVIA, ICON (which acquired PRA Health Sciences), and PPD (now part of Thermo Fisher Scientific) have been aggressively expanding their RWE and HEOR capabilities through acquisitions. This trend is forcing mid-sized and specialized players to scale up or risk being marginalized.

UBC’s acquisition of Evidinno is a clear strategic response to this competitive pressure. It significantly enhances its service portfolio, allowing it to compete more effectively for large, integrated contracts from biopharma clients who are increasingly looking to consolidate their vendors and partner with firms that can support a product across its entire lifecycle.

Under the terms of the deal, Evidinno will operate as a wholly owned subsidiary of UBC. This structure suggests a strategy to preserve Evidinno’s unique scientific culture and retain its highly specialized talent—a key asset in this knowledge-based industry—while integrating its services into UBC’s broader global platform. The combined entity is now better positioned to not only compete with the largest players but also to set new standards for quality and efficiency in evidence generation, ultimately shaping the future of how drug value is defined and demonstrated across the globe.